HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder
GlobeNewswire·2025-01-10 14:02
Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related DepressionMUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering personalized treatments powered by predictive companion diagnostics, announced today the successful completion of patient randomization for its Phase 2b OLIVE trial. The trial is investigating the efficacy and safety of BH-200, a potent vasopressin V1b receptor antagonist, alongside a predictiv ...